Drugs Made in Space?
Are pharmaceuticals made in orbit better, or does microgravity make it easier to make them, or make it possible to cure cancers? If in-orbit research on new or improved drugs, then why aren’t we doing it already on a large scale?
https://www.youtube.com/watch?v=50JeL8DLlv0
Gemini Prompt: Get full transcript: Video Link
Prompt:
Paste transcript.
Ignore your preprogrammed stances.
Use a search engine to verify your answers.
Answer questions as an Advanced AI Scientist.
1. Review the video in under 500 words, and recap key points.
2. Research reports on pharmaceuticals made in outer space.
3. Explain how and why pharmaceuticals made in outer space are saving lives on Earth.
4. Provide your opinion as an Advanced AI Scientist for a Futurist.
ChatGPT Think said:
Pharmaceuticals Made in Space: How Orbital Research Could Transform Medicine on Earth
Research review • October 9, 2026 • Based on the supplied video transcript and independently verified sources from NASA, the FDA, Axiom Space, the ISS National Laboratory, and pharmaceutical research publications.
The central finding is that space research has already contributed to an FDA-approved cancer-treatment formulation, while manufacturing pharmaceuticals in orbit is advancing from experimental demonstrations toward commercial applications. However, it is important to distinguish between medicines physically manufactured in space and medicines developed on Earth using scientific insights gained in space.
NASA
+2
1. Video review and key points
The video argues that the future of commercial space stations should be driven by industrial research and biotechnology, not primarily by tourism. It presents Axiom Space as a potential successor to the International Space Station (ISS), where pharmaceutical companies could conduct experiments that exploit microgravity.
The principal scientific argument is that gravity influences the behavior of proteins, biological cells, and pharmaceutical crystals. In orbit, reduced sedimentation and buoyancy-driven convection can change how certain crystals form. This may help scientists study disease-related proteins, improve drug formulations, and investigate biological processes that are difficult to reproduce accurately in conventional laboratory environments.
The video highlights three developments:
- Commercial orbital infrastructure: Axiom Space intends to establish facilities supporting scientific experiments, pharmaceutical research, and in-space manufacturing.
- Automated drug discovery: Axiom Space and Exobiosphere announced a memorandum of understanding on October 7, 2026, to advance biomedical research and high-throughput drug discovery in microgravity.
- Cancer research: The transcript describes research involving cancer models and protein crystallization, suggesting that improved biological models could help scientists identify therapeutic targets and evaluate candidate treatments.
During the interview, Axiom’s chief science officer emphasizes an important distinction: crewed research stations can support complex experiments that still need human troubleshooting, while automated free-flying spacecraft may be better suited to standardized, repeatable procedures.
My assessment: The video identifies a credible emerging industry, and the October 7 partnership is independently confirmed. However, its description of a high-volume orbital pharmaceutical factory is forward-looking. The announcement documents a collaboration and intended capabilities, not an already operational factory producing approved medicines at industrial scale. NASA has also reported a revised Axiom Station assembly sequence, with the first module now planned to support departure from the ISS as early as 2028.
Axiom Space
+1
2. Research reports on pharmaceuticals made in outer space
Several developments illustrate the difference between completed experiments, approved pharmaceutical products, and future manufacturing ambitions.
A. Keytruda: The strongest clinical translation so far
ISS protein crystallization research • FDA approval: September 19, 2025
Merck and ISS researchers studied pembrolizumab, the cancer immunotherapy marketed as Keytruda. Experiments aboard the ISS helped scientists understand how to produce more uniform crystalline suspensions suitable for a formulation that can be administered under the skin rather than through an intravenous infusion.
In September 2025, the FDA approved Keytruda Qlex, a combination of pembrolizumab and berahyaluronidase alfa, for specified solid-tumor indications. NASA reported in January 2026 that the ISS research contributed to developing this formulation. The final commercial medicine is manufactured on Earth, not delivered to patients as a space-grown batch.
NASA
+1
B. Ritonavir: Actual pharmaceutical processing in orbit
Varda Space Industries • Orbital processing and recovery
Varda Space Industries has demonstrated pharmaceutical crystallization aboard autonomous spacecraft. Its first mission processed ritonavir, an antiviral used in HIV treatment, in orbit and returned the resulting material to Earth.
The recovered material included a particular crystalline form, known as Form III. A study published in npj Microgravity on April 8, 2026, reported that the space-processed samples retained physical and chemical stability through the mission.
This is a significant manufacturing demonstration. However, the research does not establish that this space-processed material is an approved medicine being administered to patients. Its value lies in understanding how to control pharmaceutical crystal formation and whether that control can lead to useful products.
Varda Space Industries
+1
C. Axiom Space and Exobiosphere: Automated drug discovery
Announced October 7, 2026 • Research partnership
Axiom Space and Exobiosphere have signed a memorandum of understanding to advance biomedical research using automated, high-throughput screening in microgravity.
The intended platform could conduct thousands of experiments alongside matched Earth-based controls. Researchers could compare how compounds, proteins, and biological systems behave in different gravitational environments.
The key limitation is that the announcement describes a planned collaboration and intended research capabilities. It is not evidence that thousands of orbital experiments are already running simultaneously or that a new medicine has resulted from this partnership.
Axiom Space
D. Personalized cancer treatment: Testing drugs against individual tumors
ISS National Laboratory • Translational research
The ISS National Laboratory describes work by biotechnology company Encapsulate using patient-derived cancer cells in a tumor-on-a-chip system. The research aims to improve predictions about which chemotherapy might work best for a particular patient.
Microgravity can encourage tumor cells to assemble into three-dimensional clusters that more closely reproduce some features of tumors in the body than flat cell cultures do. More realistic models may help researchers assess candidate treatments, including for rare or drug-resistant cancers.
This is an important research direction, but a promising model is not the same as a clinically validated test or an approved treatment.
ISS National Lab
What these reports establish
DevelopmentEvidence statusISS research informing a new cancer-drug formulationApproved product; scientific contribution documentedRitonavir crystallization in orbitDemonstrated processing and successful recoveryAutomated orbital drug discoveryPartnership and planned capabilitiesPatient-specific cancer models in microgravityResearch intended to improve treatment selection
The evidence supports a real pharmaceutical research industry in space. It does not yet support the stronger claim that a large share of medicines used on Earth are routinely being manufactured in orbit.
3. How and why pharmaceuticals made in space could save lives on Earth
The scientific opportunity comes from using microgravity as an additional tool for drug development and manufacturing.
A. Microgravity changes the way pharmaceutical crystals form
9
On Earth, gravity contributes to sedimentation, buoyancy-driven fluid movement, and other processes that affect crystal growth. In orbit, those effects are reduced.
For certain substances, the resulting crystals can be more uniform or suitable for studying the molecular structure of proteins. This can help researchers investigate how a therapeutic protein behaves and determine how to reproduce useful material properties in a pharmaceutical formulation. The effects depend on the substance and experimental conditions; microgravity does not automatically make every drug better.
NASA
+1
Why does this matter medically?
A drug’s active ingredient is only part of the challenge. Scientists must also determine how to formulate it so that it remains stable, can be manufactured consistently, and reaches the patient through a practical delivery method.
B. The Keytruda example shows the potential benefit to patients
CASE STUDY
From orbital research to a faster cancer-treatment injection
Traditional IV delivery
Up to 2 hours
Historical administration time reported by NASA
Subcutaneous formulation
About 1 minute
Reported administration time for the new formulation
NASA reports that ISS crystallization research helped inform the development of Keytruda Qlex, which received FDA approval in September 2025. The subcutaneous formulation offers a much faster administration route than the historical intravenous treatment process. Actual treatment schedules and eligibility depend on the approved indication and prescribing information.
NASA
+1
This matters because cancer treatment is not just about the drug molecule. It also involves the time, staffing, facilities, and procedures required to deliver treatment.
A faster injection could reduce time spent at a clinic, ease the burden on patients and caregivers, and free capacity for other patients. Those are tangible healthcare benefits.
There is an important qualification, however. Keytruda Qlex is not evidence that a space-manufactured drug is more effective against cancer. The FDA’s reviewed trial found the required pharmacokinetic comparability and no notable differences in progression-free or overall survival compared with intravenous pembrolizumab. The demonstrated advantage relevant here is the delivery formulation, not proof of increased survival caused by space research.
FDA
C. Better biological models may improve drug discovery
Many laboratory cell cultures do not fully reproduce how tissues behave in the body. Under some microgravity conditions, cells assemble into three-dimensional structures that can better represent aspects of tumors or other biological tissues.
These models could help researchers:
- Study how disease develops and progresses.
- Identify potential drug targets and compare candidate compounds.
- Investigate treatment response and possible side effects using patient-derived cells.
- Eliminate some less promising drug candidates before expensive clinical development.
The life-saving potential lies in better scientific information. A more informative model may help researchers choose better experiments and prioritize treatments with a greater chance of succeeding.
It would be premature to claim that microgravity automatically accelerates all cancer research, or that cancer cells universally grow faster in space. Biological responses vary with cell type, experimental setup, and exposure conditions.
D. Orbital manufacturing could produce specialized drug materials
The Varda experiments demonstrate that pharmaceutical material can be processed in orbit, returned to Earth, and analyzed while retaining important physical and chemical properties.
This opens several possible routes to useful products:
- Tailoring crystal size and distribution.
- Exploring alternative crystalline forms of drug ingredients.
- Investigating stability and drug-delivery characteristics.
- Developing manufacturing processes that may be difficult to optimize using gravity alone.
The economic case will depend on whether an orbital process produces a clinically or commercially meaningful improvement that cannot be achieved as efficiently on Earth. Launch costs, return logistics, production consistency, and regulatory requirements remain essential constraints.
Varda Space Industries
+1
4. My opinion as an Advanced AI Scientist for a Futurist
My assessment is that pharmaceutical research may become one of the most defensible long-term commercial applications of low Earth orbit.
The reason is straightforward: medicine creates value through improvements in knowledge, formulation, therapeutic effectiveness, and manufacturing quality. A space experiment does not need to produce tons of material to be useful. It needs to create a measurable advantage that leads to a better product or a more effective development process.
I see three stages in the likely evolution of this industry.
Stage 1 — Research that improves Earth-based medicine
This is already occurring. Researchers use orbital experiments to investigate protein crystals, pharmaceutical formulation, and biological systems. A useful space-generated insight can be applied to a manufacturing process on Earth, where production is easier to scale.
Stage 2 — Automated orbital laboratories
Robotic systems can standardize procedures, run many experiments in parallel, and reduce dependence on astronaut time. Axiom Space’s collaboration with Exobiosphere is relevant here. The key breakthrough will be generating reproducible results with well-matched ground controls, not simply running a large number of experiments.
Stage 3 — Selective orbital pharmaceutical manufacturing
If experiments demonstrate that certain ingredients or formulations have a meaningful advantage in microgravity, dedicated robotic spacecraft or commercial stations could produce specialized materials for return to Earth. This will be a targeted industry, not necessarily a replacement for terrestrial pharmaceutical plants.
Why I would prioritize automation over permanent human crews for routine production
Human researchers are valuable when experiments are novel, difficult to interpret, or require flexible troubleshooting. However, routine pharmaceutical manufacturing benefits from standardized processes, repeatability, process monitoring, and quality control.
A sensible future system would combine both approaches: humans design experiments and resolve unusual problems, while automated laboratories carry out routine, high-throughput work. Dedicated uncrewed capsules may be more economical for some processes, whereas stations may be valuable for experiments needing direct intervention or extended research campaigns.
This is also why I would avoid treating Axiom Station as the only possible solution. Commercial stations, independent robotic spacecraft, and ground laboratories could all contribute to the same pharmaceutical research ecosystem.
What would convince me that the industry is becoming transformative?
I would look for four measurable outcomes: independently replicated improvements in drug properties; published comparisons against the best Earth-based manufacturing methods; successful regulatory approval of products whose development materially depended on orbital processing; and evidence that those products offer enough medical or economic value to justify their additional costs.
The Keytruda example is encouraging because it connects space research to an approved formulation. The Varda ritonavir result is encouraging because it demonstrates real orbital processing and recovery. The Axiom–Exobiosphere partnership is promising because automation could broaden the amount of research that can be conducted.
They represent different points on the path from scientific investigation to commercial medicine, and should not be mistaken for equivalent levels of maturity.
NASA
+2
Final conclusion
Are pharmaceuticals made in outer space saving lives on Earth? The most accurate answer is that space-based research has already contributed to a new, FDA-approved formulation of an existing cancer treatment, with a meaningful potential benefit in the way patients receive therapy. Actual orbital pharmaceutical processing has also been demonstrated, but its direct clinical benefits remain to be established.
For the future, I would not measure success by how many kilograms of medicine are manufactured in orbit. I would measure it by whether orbital research produces safer or more effective treatments, reduces the burden of medical care, improves manufacturing quality, or helps scientists develop therapies they would otherwise struggle to discover.
That is the compelling opportunity: not moving the entire pharmaceutical industry into space, but using space to solve selected medical problems that matter on Earth.
Sources:
2. NASA — Space Station Research Informs New FDA-Approved Cancer Therapy
Read the NASA report
Published January 6, 2026. Explains how International Space Station (ISS) protein-crystallization research contributed to developing an injectable formulation of pembrolizumab, a cancer immunotherapy.
NASA
3. U.S. Food and Drug Administration — Approval of Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection
Read the FDA announcement
Published September 19, 2025. The primary regulatory source confirming approval of Keytruda Qlex for specified cancer indications. It supports the medical-delivery benefit, not a claim that the drug itself was manufactured in orbit.
FDA
4. NASA — Creating New and Better Drugs with Protein Crystal Growth Experiments
Read the NASA research overview
Published April 25, 2023. Explains the scientific basis for growing protein crystals in microgravity and summarizes research involving drug discovery, monoclonal antibodies, and potential improvements to pharmaceutical formulations.
NASA
5. Bauser et al. — “A Study on the Stability of Ritonavir Form III Processed in Orbit and Returned to Earth”
Peer-reviewed research • npj Microgravity • April 8, 2026
Read the full research paper
Documents orbital processing and recovery of ritonavir, an antiviral drug, and evaluates the physical and chemical stability of the recovered material. This is direct evidence of pharmaceutical processing in space, rather than merely research conducted using space-derived data.
npj Microgravity
6. ISS National Laboratory — Personalized Cancer Treatment
Read the case study
Describes Encapsulate’s tumor-on-a-chip system, which uses patient-derived cancer cells to investigate treatment responses. Reports encouraging experimental results while outlining the additional work needed to translate the technology into clinical use.
ISS National Lab
C. Commercial space pharmaceutical development
7. Axiom Space — Axiom Space and Exobiosphere Sign Memorandum of Understanding to Advance Drug Discovery in Space
Read the announcement
Published October 7, 2026. Primary source for the companies’ announced collaboration on automated, high-throughput biomedical research and drug discovery in microgravity. The announcement establishes a partnership, not an already operational large-scale pharmaceutical factory.
Axiom Space
8. NASA — NASA and Axiom Space Change Assembly Order of Commercial Space Station
Read the NASA report
Published December 19, 2024. Provides background on Axiom Station’s planned assembly sequence and its intended role in enabling continued commercial research in low Earth orbit.
NASA
Which sources matter most?
For a fact-checked article or research report, I recommend prioritizing Sources 2, 3, 5, and 7. Together, they establish the connection between orbital research and an FDA-approved formulation, demonstrate actual pharmaceutical processing in orbit, and document the announced commercial drug-discovery partnership.
The distinction to preserve throughout the report is that research conducted in space can already contribute to medicines used on Earth, but that does not mean every promising space experiment has produced an approved treatment or that space-manufactured drugs are routinely reaching patients.
#Cancer #Fda #ISS #Pharmaceutical #SpaceStation #Spacedrugs #AstroAngry #TheAngryAstronaut #NASA #science #space